SCHEMBL5029906

SCHEMBL5029906

CC(C)(C)[Si](C)(C)OCc1ccc(CC(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.48
CAMK2A Q9UQM7 1/20 0.48
RXRA P19793 2/20 0.44
RXRB P28702 2/20 0.44
RXRG P48443 2/20 0.44
AKR1B1 P15121 1/20 0.42
HSD17B10 Q99714 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
ABCC4 O15439 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
PTGS1 P23219 1/20 0.42
HTT P42858 1/20 0.42
MITF O75030 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NR1H4 Q96RI1 2/20 0.40
EPHX2 P34913 1/20 0.40
KLKB1 P03952 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11086986 0.85 BACE1 (0.36) CA2CAMK2ARXRARXRBRXRG
SCHEMBL2852051 0.84 CYP1A2 (0.48) RXRBAKR1B1PTGS1NR1H4
SCHEMBL9435638 0.84 CYP4F2 (0.50) ALDH1A1LMNAGAAHTTSMN1; SMN2
SCHEMBL11086982 0.83 BACE1 (0.32)
SCHEMBL3722014 0.83 RXRA (0.51) RXRARXRBRXRGALDH1A1HPGD
SCHEMBL1501623 0.82 L3MBTL1 (0.49) RXRARXRBRXRGALDH1A1GAA
SCHEMBL6303196 0.81 SMN1; SMN2 (0.54) RXRARXRBALDH1A1TSHRSMN1; SMN2
SCHEMBL2506528 0.81 SRD5A2 (0.46) CA2CAMK2ARXRARXRBRXRG
SCHEMBL906834 0.80 IDO1 (0.48) HSD17B10HPGDLMNATSHR
SCHEMBL10140463 0.80 CYP4F2 (0.40) ALDH1A1LMNAGAAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP disclosed
US-12303510-B2 Inhibitory effect of low molecular weight compound on cancer and fibrosis NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2025-05-20 US disclosed
EP-4452942-A1 NANOMATERIALS COMPRISING DISULFIDES Beam Therapeutics Inc. (US) 2024-10-30 EP disclosed
US-20240335542-A1 NANOMATERIALS COMPRISING DISULFIDES BEAM THERAPEUTICS INC. 2024-10-10 US disclosed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
WO-2023121964-A1 NANOMATERIALS COMPRISING DISULFIDES BEAM THERAPEUTICS INC. (US) 2023-06-29 WO disclosed
WO-2023121964-A1 NANOMATERIALS COMPRISING DISULFIDES BEAM THERAPEUTICS INC. (US) 2023-06-29 WO disclosed
US-11213527-B2 Inhibitory effect of low molecular weight compound on cancer and fibrosis NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2022-01-04 US disclosed
US-20210386747-A1 INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS KANONCURE, INC. (JP) 2021-12-16 US disclosed
CN-108026104-B Cancer and fibrosis inhibition and regeneration promotion effects using low-molecular-weight compound 国立大学法人鸟取大学 2021-06-18 CN disclosed
US-20190055249-A1 SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) 2019-02-21 US disclosed
EP-3366687-A1 SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS National University Corporation Tottori University (JP) 2018-08-29 EP disclosed
CN-108026104-A The suppression of cancer and fibrosis and the effect of regeneration promotion using low molecular compound 国立大学法人鸟取大学 2018-05-11 CN disclosed
US-20180028536-A1 INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS KANONCURE, INC. (JP) 2018-02-01 US disclosed
US-9650414-B1 Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof SIMON FRASER UNIVERSITY (CA) 2017-05-16 US disclosed
US-9650414-B1 Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof SIMON FRASER UNIVERSITY (CA) 2017-05-16 US disclosed
EP-3150207-A1 INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS National University Corporation Tottori University (JP) 2017-04-05 EP disclosed
CN-106132417-A Cancer and fibrosis inhibiting effects of low molecular weight compound 国立大学法人鸟取大学 2016-11-16 CN disclosed
WO-2015147107-A1 INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS 国立大学法人鳥取大学 2015-10-01 WO disclosed
EP-1916239-A1 PYRIDONE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12303510-B2 Inhibitory effect of low molecular weight compound on cancer and fibrosis MMP1, SERPINB1, LGALS1 CA2 3267/4885CAMK2A 3132/4885RXRA 2022/4885
US-20240335542-A1 NANOMATERIALS COMPRISING DISULFIDES GPX4, GPX1, ABCB7 CA2 4205/4885CAMK2A 3892/4885RXRA 1441/4885
US-20190055249-A1 SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS HDGF, SHC1, HGF CA2 4044/4885CAMK2A 1386/4885RXRA 961/4885
US-11213527-B2 Inhibitory effect of low molecular weight compound on cancer and fibrosis MMP1, SERPINB1, LGALS1 CA2 3267/4885CAMK2A 3132/4885RXRA 2022/4885
US-20210386747-A1 INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS MMP1, SERPINB1, LGALS1 CA2 3267/4885CAMK2A 3132/4885RXRA 2022/4885
US-20180028536-A1 INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS MMP1, SERPINB1, LGALS1 CA2 3267/4885CAMK2A 3132/4885RXRA 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.